Amgen's Kyprolis fails to show OS casting shadow on European future
This article was originally published in Scrip
Executive Summary
Amgen's cancer drug Kyprolis (carfilzomib) failed to meet the primary endpoint of improving overall survival in patients with relapsed and advanced refractory multiple myeloma in the Phase III FOCUS trial.